Pfizer Pharmaceutical Company: The World's Largest Pharmaceutical Company

Pfizer Pipeline – Our Medicines in Development

Our pipeline of new medicines in development is the largest in the pharmaceutical industry, focusing on a broad range of unmet medical needs spanning 10 Therapeutic Areas. Pfizer invests more than $7 billion annually in the research and development of new products across more therapeutic areas than any other company in our industry. Relying on the strength of our pipeline and scientific talent, Pfizer has generated a steady stream of breakthroughs over the years. Our researchers continue to work around the clock and around the globe to ensure the best medicines for our patients in the years to come.

Download a PDF of the product candidates in Pfizer's human prescription medicine pipeline as of March 31, 2009. Content includes:

  • New chemical entities in our portfolio from Phase 1 of development through to first major approval in the United States or Europe.
  • New therapeutic indications or enhancements for our Phase 2 and 3 development programs and/or currently marketed medicines and selected other medicines which target unmet medical need or represent significant commercial opportunities.

Pfizer Pipeline as of March 31, 2009

Read press release issued April 2, 2009

Looking for a Pfizer Product?
A B-D E-H
I-N O-P R-Z
A-B C D-E
F-L M-P R-U V-Z
Conducting Research & Clinical Trials

Read Pfizer's commitment to conducting ethical research, ensuring the safety and privacy of patients and how we approach clinical trials.

How Trials Work
Pfizer 2007 Corporate Citizenship Report

Learn about the four phases of clinical trials and the importance of each in ensuring the safety and effectiveness of medical treatments.